Cargando…

Apoptosis deregulation in myeloproliferative neoplasms

Philadelphia-chromosome negative chronic myeloproliferative neoplasms are clonal hematologic diseases characterized by hematopoietic progenitor independence from or hypersensitivity to cytokines. The cellular and molecular mechanisms involved in the pathophysiology of myeloproliferative neoplasms ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tognon, Raquel, Nunes, Natália de Souza, de Castro, Fabíola Attié
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Instituto Israelita de Ensino e Pesquisa Albert Einstein 2013
Materias:	Reviewing Basic sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880398/ https://www.ncbi.nlm.nih.gov/pubmed/24488400 http://dx.doi.org/10.1590/S1679-45082013000400025

Ejemplares similares

Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
por: Cacemiro, Maira da Costa, et al.
Publicado: (2018)

Erratum on “Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation”
por: Cacemiro, Maira da Costa, et al.
Publicado: (2021)

Philadelphia-negative myeloproliferative neoplasms display alterations in monocyte subpopulations frequency and immunophenotype
por: Bassan, Vitor Leonardo, et al.
Publicado: (2022)

Philadelphia-negative chronic myeloproliferative neoplasms
por: Bittencourt, Rosane Isabel, et al.
Publicado: (2012)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

Inferring the initiation and development of myeloproliferative neoplasms
por: Hermange, Gurvan, et al.
Publicado: (2022)

Molecular biology of Philadelphia-negative myeloproliferative neoplasms
por: Campregher, Paulo Vidal, et al.
Publicado: (2012)

33886 Deregulation of the LANCL2 Pathway in Alzheimer's Disease
por: Birnbaumria, Emily, et al.
Publicado: (2021)

IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2(V617F)-positive myeloproliferative neoplasms
por: de Melo Campos, Paula, et al.
Publicado: (2016)

Guidelines for the management of myeloproliferative neoplasms
por: Choi, Chul Won, et al.
Publicado: (2015)

Targeted therapies for myeloproliferative neoplasms
por: Li, Bing, et al.
Publicado: (2019)

Experimental Modeling of Myeloproliferative Neoplasms
por: Lanikova, Lucie, et al.
Publicado: (2019)

Novel therapeutics in myeloproliferative neoplasms
por: Venugopal, Sangeetha, et al.
Publicado: (2020)

Molecular pathogenesis of the myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2021)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

Bone Marrow Soluble Mediator Signatures of Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
por: Cominal, Juçara Gastaldi, et al.
Publicado: (2021)

Bone marrow niche dysregulation in myeloproliferative neoplasms
por: Curto-Garcia, Natalia, et al.
Publicado: (2020)

Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis
por: Tognon, Raquel, et al.
Publicado: (2012)

The Hematopoietic Niche in Myeloproliferative Neoplasms
por: Schmitt-Graeff, Annette H., et al.
Publicado: (2015)

Mutant Calreticulin in the Myeloproliferative Neoplasms
por: Prins, Daniel, et al.
Publicado: (2020)

Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
por: Kjær, Lasse
Publicado: (2020)

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
por: Palomo, Laura, et al.
Publicado: (2021)

NK Cells in Myeloproliferative Neoplasms (MPN)
por: Naismith, Erin, et al.
Publicado: (2021)

Functional Consequences of Mutations in Myeloproliferative Neoplasms
por: Constantinescu, Stefan N., et al.
Publicado: (2021)

The Contribution of JAK2 46/1 Haplotype in the Predisposition to Myeloproliferative Neoplasms
por: Paes, Jhemerson, et al.
Publicado: (2022)

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
por: Gianelli, Umberto, et al.
Publicado: (2022)

The microenvironment in myeloproliferative neoplasm
por: Méndez-Ferrer, Simón, et al.
Publicado: (2018)

Spleen in myeloproliferative neoplasms
por: Barosi, Giovanni
Publicado: (2018)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Cytokines frequently implicated in myeloproliferative neoplasms
por: Wang, Yingying, et al.
Publicado: (2019)

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
por: de Freitas, Renata Mendes, et al.
Publicado: (2015)

Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives
por: Vannucchi, Alessandro M, et al.
Publicado: (2009)

SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms
por: Aujla, Amandeep, et al.
Publicado: (2018)

The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms
por: Belčič Mikič, Tanja, et al.
Publicado: (2021)

The 2020 revision of the guidelines for the management of myeloproliferative neoplasms
por: Kim, Sung-Yong, et al.
Publicado: (2021)

Thrombotic and Hemorrhagic Issues Associated with Myeloproliferative Neoplasms
por: Papageorgiou, Loula, et al.
Publicado: (2022)

Practical management of the haemorrhagic complications of myeloproliferative neoplasms
por: Jones, Edward, et al.
Publicado: (2022)

Reversine exhibits antineoplastic activity in JAK2(V617F)-positive myeloproliferative neoplasms
por: Lima, Keli, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j66jfbum3a87gv0d81u1vmcrfh